MedTrace Logo

TRAMmoniTTR Study Genetic Screening of an At-risk Population for hATTR and Monitoring of TTR Positive Subjects

NCT03237494 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 5028

Last updated 2025-06-29

No results posted yet for this study

Summary

National, multicenter, epidemiological, longitudinal protocol to investigate the hATTR prevalence in an at-risk population for Hereditary Transthyretin Amyloidosis (hATTR) and subjects diagnosed with hATTR, to monitor the clinical status in TTR positive subjects and to establish hATTR biomarker/s

Conditions

  • Transthyretin Amyloidosis
  • Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy
  • Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy
  • Polyneuropathies
  • Cardiomyopathies

Sponsors & Collaborators

Principal Investigators

  • Peter Bauer, Prof. · Centogene GmbH

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-20
Primary Completion
2025-05-16
Completion
2025-05-16

Countries

  • Austria
  • Germany
  • Switzerland

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03237494 on ClinicalTrials.gov